Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPX NASDAQ:PBYI NASDAQ:RANI NASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPXCompass Therapeutics$2.02-1.5%$2.90$1.61▼$6.88$369.18M0.893.96 million shs9.27 million shsPBYIPuma Biotechnology$7.56+4.6%$7.26$3.03▼$7.90$368M1.21189,295 shs427,438 shsRANIRani Therapeutics$0.78+2.2%$0.91$0.39▼$3.87$94.79M0.74915,570 shs303,043 shsSNDLSNDL$1.42-1.4%$1.45$1.15▼$2.89$370.65M0.912.06 million shs2.09 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPXCompass Therapeutics-1.46%+0.50%+11.60%-60.78%-15.13%PBYIPuma Biotechnology+4.56%+4.56%+11.01%+23.53%+122.35%RANIRani Therapeutics+2.25%-2.44%-11.53%-30.76%+54.02%SNDLSNDL-1.39%-2.74%+2.90%+5.19%+11.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPXCompass Therapeutics$2.02-1.5%$2.90$1.61▼$6.88$369.18M0.893.96 million shs9.27 million shsPBYIPuma Biotechnology$7.56+4.6%$7.26$3.03▼$7.90$368M1.21189,295 shs427,438 shsRANIRani Therapeutics$0.78+2.2%$0.91$0.39▼$3.87$94.79M0.74915,570 shs303,043 shsSNDLSNDL$1.42-1.4%$1.45$1.15▼$2.89$370.65M0.912.06 million shs2.09 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPXCompass Therapeutics-1.46%+0.50%+11.60%-60.78%-15.13%PBYIPuma Biotechnology+4.56%+4.56%+11.01%+23.53%+122.35%RANIRani Therapeutics+2.25%-2.44%-11.53%-30.76%+54.02%SNDLSNDL-1.39%-2.74%+2.90%+5.19%+11.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPXCompass Therapeutics 2.86Moderate Buy$12.91539.06% UpsidePBYIPuma Biotechnology 2.00HoldN/AN/ARANIRani Therapeutics 2.60Moderate Buy$8.751,018.35% UpsideSNDLSNDL 2.00Hold$5.00252.11% UpsideCurrent Analyst Ratings BreakdownLatest RANI, PBYI, CMPX, and SNDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026SNDLSNDL Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/4/2026CMPXCompass Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/1/2026CMPXCompass Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$6.005/28/2026SNDLSNDL Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/20/2026RANIRani Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/11/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)4/29/2026SNDLSNDL Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/28/2026CMPXCompass Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/28/2026CMPXCompass Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $7.004/28/2026CMPXCompass Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$10.004/27/2026CMPXCompass Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.00(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPXCompass Therapeutics$850K427.98N/AN/A$1.11 per share1.82PBYIPuma Biotechnology$228.40M1.68$0.87 per share8.67$2.59 per share2.92RANIRani Therapeutics$1.63M59.46N/AN/A$0.34 per share2.30SNDLSNDL$677.32M0.54$0.11 per share12.79$3.06 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPXCompass Therapeutics-$66.49M-$0.41N/AN/AN/AN/A-39.75%-35.29%8/10/2026 (Estimated)PBYIPuma Biotechnology$31.11M$0.4815.7568.73N/A10.69%20.30%12.05%8/6/2026 (Estimated)RANIRani Therapeutics-$29.67M-$0.41N/AN/AN/AN/A-206.46%-83.95%8/6/2026 (Estimated)SNDLSNDL-$11.29M-$0.03N/A35.50N/A-1.19%-1.02%-0.85%7/30/2026 (Estimated)Latest RANI, PBYI, CMPX, and SNDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026RANIRani Therapeutics-$0.06-$0.04+$0.02-$0.04$1.13 million$1.71 million5/7/2026Q1 2026PBYIPuma Biotechnology-$0.13-$0.04+$0.09-$0.07$42.00 million$44.81 million5/5/2026Q1 2026CMPXCompass Therapeutics-$0.10-$0.10N/A-$0.10($0.82) millionN/A3/26/2026Q4 2025RANIRani Therapeutics-$0.03-$0.07-$0.04-$0.07$5.00 million$1.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCMPXCompass TherapeuticsN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPXCompass TherapeuticsN/A19.0419.04PBYIPuma BiotechnologyN/A2.382.24RANIRani TherapeuticsN/A3.403.40SNDLSNDL0.124.843.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPXCompass Therapeutics68.43%PBYIPuma Biotechnology61.29%RANIRani Therapeutics30.19%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipCMPXCompass Therapeutics18.70%PBYIPuma Biotechnology22.20%RANIRani Therapeutics26.73%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPXCompass Therapeutics20180.09 million146.41 millionNot OptionablePBYIPuma Biotechnology20050.90 million39.60 millionOptionableRANIRani Therapeutics110123.88 million90.77 millionOptionableSNDLSNDL2,751257.40 millionN/AOptionableRANI, PBYI, CMPX, and SNDL HeadlinesRecent News About These CompaniesRegulator ordered cannabis producer SNDL to sell Ontario stores or risk having licences revoked, letter showsJune 12, 2026 | theglobeandmail.comCORRECTING and REPLACING Sundial Media & Technology Group Names Cedric J. Rogers Chief Product & Platform OfficerJune 2, 2026 | businesswire.comSundial Media & Technology Group Formally Establishes Chief Product & Platform Officer Role, Names Cedric J. Rogers to Lead Creator Ecosystem StrategyJune 2, 2026 | businesswire.comAfter Rough Q1, SNDL Inc (SNDL) Sees Cannabis Market ImprovingMay 31, 2026 | finance.yahoo.comSNDL Drops Ontario Store Acquisition, Shifts Capital to Share BuybacksMay 30, 2026 | theglobeandmail.com1CM Provides Update on Arrangement Agreement with SNDLMay 27, 2026 | finance.yahoo.comSNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis StoresMay 27, 2026 | finance.yahoo.com1CM Provides Update on Arrangement Agreement with SNDLMay 27, 2026 | newsfilecorp.comNSNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis StoresMay 27, 2026 | financialpost.comFSNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis StoresMay 27, 2026 | globenewswire.comMay 2026's Promising Penny Stocks To ConsiderMay 25, 2026 | finance.yahoo.comTop Canadian Marijuana Stock Choices For Better Investing In 2026May 22, 2026 | marijuanastocks.comMAlliance Global Partners Keeps Their Buy Rating on SNDL (SNDL)May 6, 2026 | theglobeandmail.comATB Cormark Capital Markets Keeps Their Buy Rating on SNDL (SNDL)May 6, 2026 | theglobeandmail.comShould SNDL Stock Be in Your Portfolio Post Q1 Earnings?May 6, 2026 | finance.yahoo.comShould SNDL Stock Be in Your Portfolio Post Q1 Earnings?May 6, 2026 | zacks.comSNDL Inc. (SNDL) Reports its First-quarter 2026 ResultsMay 1, 2026 | finance.yahoo.comSNDL Inc. (SNDL) Reports its First-quarter 2026 ResultsMay 1, 2026 | insidermonkey.comSNDL Inc. Q1 2026 Earnings Call SummaryApril 30, 2026 | finance.yahoo.comSNDL Quarterly Revenue Dented By Soft Liquor, Cannabis Market ConditionsApril 30, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026Aggressive Insider Buying Signals Opportunity in 3 Risky StocksBy Thomas Hughes | June 2, 2026Uranium Energy Corp Melts Down—Nuclear Opportunity at HandBy Thomas Hughes | June 10, 2026AI's Power Crunch Is Putting Uranium Energy Back on Investors' WatchlistsBy Jessica Mitacek | June 3, 2026RANI, PBYI, CMPX, and SNDL Company DescriptionsCompass Therapeutics NASDAQ:CMPX$2.02 -0.03 (-1.46%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$2.04 +0.02 (+1.24%) As of 06/18/2026 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Puma Biotechnology NASDAQ:PBYI$7.56 +0.33 (+4.56%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$7.58 +0.02 (+0.20%) As of 06/18/2026 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Rani Therapeutics NASDAQ:RANI$0.78 +0.02 (+2.25%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.78 0.00 (-0.18%) As of 06/18/2026 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.SNDL NASDAQ:SNDL$1.42 -0.02 (-1.39%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$1.43 +0.01 (+0.70%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
